Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer

• 来源期刊: 亚洲男性学杂志（英文版）
• 年，卷（期）: 2015,（3）
• 页码范围: 439-440
• 页数: 2页
• 语种: 中文
• DOI: 10.4103/1008-682X.145069

摘要

The recent manuscript in New England Journal of Medicine by Antonarakis et al.1 has important clinical implications.This study evaluates mRNA expression of a particular androgen receptor splice variant-7 (AR-V7),in circulating tumor cells (CTCs) from metastatic castrate-resistant prostate cancer (mCRPC)patients receiving enzalutamide or abiraterone.The findings were striking,none of the 18 patients with detectable AR-V7 in CTCs had prostate-specific antigen (PSA) responses.Further,the median time to PSA progression after enzalutamide or abiraterone treatment was only 1.3-1.4 months in AR-V7-positive patients as compared to 5.3-6.1 months in ARoV7 negative patients.AR-V7 in CTCs was also associated with shorter survival.